We are exploring whether the medication AP1189 can improve kidney function and reduce protein in urine for patients with idiopathic membranous nephropathy. This study involves patients already receiving ACE inhibitors or angiotensin II receptor blockers.
Health conditions and diseases that the clinical trial is designed to study and treat.
Membranous nephropathy is a kidney disorder that causes the body to leak large amounts of protein into the urine, leading to symptoms like swelling, high blood pressure, and fatigue. It can be idiopathic, meaning the cause is unknown, or secondary to other conditions.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
